Production of tacrolimus (fk-506) using new streptomyces species
AssigneeRanbaxy Laboratories Limited
InventorsParveen Kumar, Sunita Sharma, Aniruddha Shukla, Sundeep Kumar, Raj Maurya, Vikas Katial, Ashoke Mitra, Paresh Gigras
Life of this patent
Estimating the term…
Abstract
The invention relates to a new microorganism Streptomyces glaucescens MTCC 5115 and a process for producing the immunosuppressant agent, tacrolimus (FK-506) utilizing the new microorganism Streptomyces glaucescens MTCC 5115. The invention also relates to pharmaceutical compositions that include the tacrolimus (FK-506) and use of said compositions for treatment or prevention of the transplantation rejection of organs or tissues such as heart, kidney, liver, medulla ossium, skin, etc.
Claims20
An isolated microorganism Streptomyces glaucescens MTCC 5115.
A fermentation process for producing tacrolimus (FK-506) of Formula I,
- the process comprising using isolated Streptomyces glaucescens MTCC 5115.
A process for producing tacrolimus, the process comprising the steps of culturing a strain of Streptomyces glaucescens MTCC 5115 or mutant thereof under submerged aerobic fermentation conditions in an aqueous nutrient medium;
- and isolating the tacrolimus from said medium.
Dependencies are inferred from the claim text.